Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C21H27NO5 |
Molecular Weight | 373.4428 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H](NCCC1=CC(C)=C(OCC(O)=O)C=C1C)[C@H](O)C2=CC=C(O)C=C2
InChI
InChIKey=VMMYRRFPMAGXNP-BTYIYWSLSA-N
InChI=1S/C21H27NO5/c1-13-11-19(27-12-20(24)25)14(2)10-17(13)8-9-22-15(3)21(26)16-4-6-18(23)7-5-16/h4-7,10-11,15,21-23,26H,8-9,12H2,1-3H3,(H,24,25)/t15-,21-/m0/s1
Molecular Formula | C21H27NO5 |
Molecular Weight | 373.4428 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Ritobegron (KUC 7483) is a selective β3-adrenoceptor agonist that was developed for oral treatment of overactive bladder. It is the prodrug of the active compound KUC-7322. Phase I studies have investigated the pharmacodynamic and pharmacokinetic effects of ritobegron in healthy individuals and patients with spinal cord injury. Ritobegron exhibits a high selectivity for the bladder versus other organs, and decreased intravesical pressure with minimal effects on the cardiovascular system in rats. When administered in combination with organic anion transporter (OAT) inhibitors such as probenecid (primarily used in treating gout and hyperuricemia), the plasma concentration of the active compound KUC-7322 may increase.
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:09:15 GMT 2023
by
admin
on
Fri Dec 15 16:09:15 GMT 2023
|
Record UNII |
LD86RKR53M
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C48149
Created by
admin on Fri Dec 15 16:09:15 GMT 2023 , Edited by admin on Fri Dec 15 16:09:15 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
300000034433
Created by
admin on Fri Dec 15 16:09:15 GMT 2023 , Edited by admin on Fri Dec 15 16:09:15 GMT 2023
|
PRIMARY | |||
|
9820882
Created by
admin on Fri Dec 15 16:09:15 GMT 2023 , Edited by admin on Fri Dec 15 16:09:15 GMT 2023
|
PRIMARY | |||
|
8490
Created by
admin on Fri Dec 15 16:09:15 GMT 2023 , Edited by admin on Fri Dec 15 16:09:15 GMT 2023
|
PRIMARY | |||
|
C576374
Created by
admin on Fri Dec 15 16:09:15 GMT 2023 , Edited by admin on Fri Dec 15 16:09:15 GMT 2023
|
PRIMARY | |||
|
255734-04-4
Created by
admin on Fri Dec 15 16:09:15 GMT 2023 , Edited by admin on Fri Dec 15 16:09:15 GMT 2023
|
PRIMARY | |||
|
CHEMBL2107773
Created by
admin on Fri Dec 15 16:09:15 GMT 2023 , Edited by admin on Fri Dec 15 16:09:15 GMT 2023
|
PRIMARY | |||
|
LD86RKR53M
Created by
admin on Fri Dec 15 16:09:15 GMT 2023 , Edited by admin on Fri Dec 15 16:09:15 GMT 2023
|
PRIMARY | |||
|
DTXSID50870290
Created by
admin on Fri Dec 15 16:09:15 GMT 2023 , Edited by admin on Fri Dec 15 16:09:15 GMT 2023
|
PRIMARY | |||
|
C87677
Created by
admin on Fri Dec 15 16:09:15 GMT 2023 , Edited by admin on Fri Dec 15 16:09:15 GMT 2023
|
PRIMARY | |||
|
DB12080
Created by
admin on Fri Dec 15 16:09:15 GMT 2023 , Edited by admin on Fri Dec 15 16:09:15 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> AGONIST |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PRODRUG -> METABOLITE ACTIVE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|